CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive ...

Core Points - Prime Medicine, Inc. announced a public offering of 38,000,000 shares at a price of $3.30 per share, aiming to raise approximately $125.4 million in gross proceeds before expenses [1] - The offering includes a 30-day option for underwriters to purchase an additional 5,700,000 shares [1] - The offering is expected to close around August 1, 2025, pending customary closing conditions [1] Company Overview - Prime Medicine is a biotechnology company focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform, which allows for precise gene editing [6] - The company is advancing a portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology, targeting diseases with well-understood biology [7] Offering Details - The shares are being offered under an effective shelf registration statement filed with the SEC on November 3, 2023, and declared effective on November 13, 2023 [3] - The final prospectus supplement will be filed with the SEC and will be available through designated contacts [4]